Skip to main content

Table 2 Baseline characteristics and plasma drug concentrations in males and non-pregnant females with acute ocular toxoplasmosis, both assayed in the advisory laboratory using liquid chromatography–mass spectrometry (LC–MS)

From: Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case–control study

  OT p-value
  Malea Femaleb
Age
 N 10 17 p = 0.841a
 Mean ± SD [95% CI] 26.6 ± 8.7 [20.4; 32.8] 26.1 ± 5.3 [23.6; 28.5]
 Min–max 16–48 17–35
 Median 25 27
 Percentiles (25th; 75th) 21; 29 21; 29
Days after treatment start
 N 10 17 p = 0.083b
 Mean ± SD 13 ± 2 14 ± 2
 Min–max 10–15 11–17
 Median [95% CI]d 14 [12; 14] 14 [14; 16]
 Percentiles (25th; 75th) 12; 14 13; 16
PY (µg/l)
 N 10 17 p = 0.537b
 Mean ± SD 1527 ± 667 1550 ± 1411
 Min–max 789–2630 29–6160
 Median [95% CI]d 1321 [962; 2140] 1230 [780; 1890]
 Percentiles (25th; 75th) 962; 2140 780; 1980
SA [mg/l)c
 N 10 17 p = 0.386b
 Mean ± SD 82.4 ± 47.9 69.1 ± 44.2
 Min–max 9.0–159.0 9.0–166.0
 Median [95% CI]d 82.4 [53.5; 115.0] 70.4 [52.4; 89]
 Percentiles (25th; 75th) 53.5; 115 52.4; 89.0
  1. a t-test for independent samples
  2. b Mann–Whitney U test
  3. c Detection limit set to 9.0 mg/l
  4. d 95% confidence intervals of the median were calculated using bootstrapping